Key result
Cardiac contractility modulation therapy improved right ventricular systolic function at 6 months, increasing TAPSE from 16.6 to 18.5 mm.
Why the study?
Little evidence was available regarding the effects of cardiac contractility modulation on right ventricular function and right ventricular-pulmonary artery coupling.
Does cardiac contractility modulation therapy improve right ventricular function and RV-pulmonary artery coupling in patients with HFrEF?
Observational (n=21)
Does cardiac contractility modulation therapy improve right ventricular function and RV-pulmonary artery coupling in patients with HFrEF?
Cardiac contractility modulation therapy is associated with significant improvements in right ventricular systolic function and RV-pulmonary artery coupling at 6 months in patients with HFrEF.
Answers are grounded in this paper and cite their sources.
May support CCM for RV function in HFrEF; hypothesis-generating from cohort data, RCTs needed.
Background. Cardiac contractility modulation (CCM) is a novel device-based therapy for patients with heart failure with reduced and mild reduced ejection fraction (HFrEF/HFmrEF). CCM increases cardiac performance and produces reverse left ventricular remodeling, with improved symptoms, functional capacity, quality of life, and reduced HF-related hospitalizations. However, to date, little evidence is available on the effects of CCM on right ventricle (RV) function. Therefore, we analyzed the effects of CCM on RV systolic function and RV–pulmonary artery (PA) coupling. Methods. Twenty-one (65 ± 12.5 years) patients with NYHA class III, ejection fraction < 40% and QRS < 120 ms were assessed at baseline. During follow up, two patients had died, and so nineteen patients were evaluated six months after CCM therapy. Using echocardiography, tricuspid annular systolic excursion (TAPSE), myocardial systolic excursion velocity (RVs), and RV free-wall strain was measured. PA systolic pressure (PASP) was estimated from tricuspid regurgitation, adding the right atrial pressure estimation. The RV-PA coupling was calculated as TAPSE/PASP ratio. Results. After six months, patients who underwent CCM therapy showed a reduction in RV diameters and improved RV systolic function, as evidenced by the increase in both TAPSE (16.6 ± 4.2 mm vs. 18.5 ± 3.6 mm; p < 0.05), RVs (10.1 ± 1.8 cm/s vs. 11.3 ± 11.4 cm/s; p < 0.05), and RV strain (−13.7 ± 1.8% vs. −15.6 ± 2.3%; p < 0.05). CCM also determined a reduction in PASP (34.2 ± 9.8 mmHg vs. 28 ± 6.2 mmHg; p < 0.05) and an increase in the TAPSE/PASP ratio (0.52 ± 0.14 mm/mmHg vs. 0.66 ± 0.23 mm/mmHg; p < 0.05). Conclusions. At six months, CCM increases RV reverse remodeling and performance, reducing RV size and improving RV systolic function, PASP, and RV-PA coupling.
No takes yet. Share an insight, caveat, or question.
Contaldi et al. (2022) conducted an observational in Heart failure with reduced and mild reduced ejection fraction (HFrEF/HFmrEF) (n=21). Cardiac contractility modulation (CCM) vs. Baseline was evaluated on Tricuspid annular systolic excursion (TAPSE) (p=< 0.05). Cardiac contractility modulation therapy improved right ventricular systolic function at 6 months, increasing TAPSE from 16.6 to 18.5 mm.
Synapse has enriched 10 related papers. Consider them for comparative context: